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SUMMARY 
A single injection of low doses of botulinum toxin type A (3.5 U/kg) completely abolished 
secondary mechanical hyperalgesia throughout its duration in a model of postsurgical pain 
after gastrocnemius incision in rat.  
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INTRODUCTION 
Nearly 50% of surgical patients suffer from intense post surgical pain [1]. Opioids and non-opioid 
drugs are used to alleviate this problem, but it persists to be an issue. 
The most common experimental approach to the study of postsurgical hyperalgesia is the incisional 
model of pain [2]. Diverse drugs reduce incision-induced mechanical hyperalgesia in rats, but only 
morphine has been proven to be 100% effective, with results lasting only for a few hours [3].  
There is a continually rising number of reports suggesting long-lasting antinociceptive effect 
of botulinum toxin type A (BTX-A) in both humans and animals [4, 5]. It is generally 
assumed that the mechanism of BTX-A-induced antinociception might be the prevention of 
neurotransmitter release from the primary sensory neurons [6]. Here we report that single 
injection of BTX-A completely abolished secondary hyperalgesia after gastrocnemius incision 
in rats. 
MATERIALS AND METHODS 
A total number of 50 male Wistar rats (300-350 g) were included in the study. The Principles of 
Laboratory Animal Care (NIH Publication 86-23, 1985) were followed, and approval was granted by 
the Ethical Committee, Zagreb School of Medicine.  
Drugs: botulinum toxin type A (BOTOX, Allergan, USA); chloral hydrate and ethanol (Sigma, St. 
Louis, USA).  
Forty-five animals were anaesthetized by a single intraperitoneal injection of chloral hydrate (300 
mg/kg). A 3 cm longitudinal incision was made through the skin of the midportion of the posterior 
hind limb starting 1-1.5 cm from the edge of the heel and extending to the popliteral region [2].  
Longitudinal incision of gastrocnemius muscle (parallel with muscular fibers) was done. After 
hemostasis, the skin was sutured. Sutures were removed 3 days after the procedure. 
Five unoperated rats served as control. Sensitivity to mechanical stimuli was measured in terms of 
paw withdrawal after painful pressure as described by Randall and Selitto [7]. The measurements 
were performed 3 times in 10-min intervals. The experimenter was unaware of the treatment groups. 
Animals which developed secondary hyperalgesia (27 out of 45) after 24 h (paw-withdrawal 
threshold reduced for at least 35% compared to the unoperated controls) were injected 
subcutaneously either with saline or BTX-A (1, 3.5 and 7 U/kg, ) into the plantar surface of the 
hindpaw pad (in a volume 20 l). In the time-course experiment, mechanical sensitivity was 
measured on day 1, 6, 10 and 14 following the BTX-A injection. 
Results are presented as mean±SE. Statistical analysis was performed using ANOVA and Neumann–
Keuls post-hoc test. In the time-course experiment, two-way ANOVA for repeated measurements 
followed by Tukey’s test was applied. P<0.05 was considered significant. 
RESULTS AND DISCUSSION 
BTX-A (3.5 U/kg and 7 U/kg) produced a complete reversal of mechanical hyperalgesia measured on 
day 6 after the toxin application (Figure 1). Since paw withdrawal was measured, results might be 
influenced by decreased muscular strength which, in turn, could be induced by BTX-A. However, it 
was previously shown by Cui et al. [8] (and in our laboratory: unpublished) that BTX-A in a dose of 
7 U/kg did not affect motor performance in the rotarod test. 
BTX-A (3.5 U/kg) did not influence mechanical pain threshold on day 1 after its application.  
However, on days 6 and 10, BTX-A completely abolished the secondary mechanical hyperalgesia 
(Figure 2). This is in line with our previous report on experimental neuropathy where BTX-A 
reduced hyperalgesia starting from day 5 and lasting for 10 more days [5]. On day 14 following the 
gastrocnemius incision, there was no difference between the tested groups (Figure 2), indicating that 
postsurgical hyperalgesia ceased. Our results are in line with three open label clinical trials. Dohin et 
al. found that intramuscular BTX-A pretreatment decreases the duration of postoperative pain and 
improves the comfort in 9 children with cerebral palsy after limb surgery [9]. Wittenkindt et al. [10] 
report reduced chronic and shooting pain lasting 4 weeks after subcutaneous injection of BTX-A in 
16 patients after neck dissection. They also report similar results, pain reduction after a single 
subcutaneous injection of BTX-A in 13 patients after neck dissection, in their more recent dose-
finding study [11]. 
Keeping in mind the number of patients suffering from postsurgical pain and inadequate 
treatments, our finding that single BTX-A injection completely abolished hyperalgesia for at 
least 10 days in the experimental model of postsurgical pain seems to be of major importance. 
Together with three before-mentioned clinical trials, our findings emphasize the need for 
further controlled clinical trials. 
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Figure 1 Dose-dependent antinociceptive effect of BTX-A on mechanical hyperalgesia in 
experimental model of postsurgical pain. Measurements were done on day 6 after BTX-A 
subcutaneous application into the rat hindpaw.  
Control – saline-treated unoperated animals (n=5); gastrocnemius incision – saline-treated 
group after gastrocnemius incision (n=6); BTX 1 U/kg (n=7), BTX 3.5 U/kg (n=8) and BTX 
7 U/kg (n=6) - BTX-A-treated groups after gastrocnemius incision. Mean ±SE,  *p<0.001 
compared to control; +p<0.001 compared to gastrocnemius incision (ANOVA and Newman-
Keuls post hoc test)  
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Figure 2 Time-course of the antinociceptive effect of BTX-A (3.5 U/kg) on mechanical 
hypersensitivity in experimental model of postsurgical pain. 
■ Black bars – saline-treated unoperated controls (n=5); □ – White bars- saline-treated group 
after gastrocnemius incision (n=6); ■- Gray bars - BTX-A treated group after gastrocnemius 
incision (n=8).  Mean±SE,  *p<0.01, **p<0.001 compared to saline-treated unoperated 
controls; +p<0.01 compared to saline-treated group after gastrocnemius incision (ANOVA for 
repeated measurements followed by Tukey HSD test) 
 
